MetLife Investment Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $7.7M | Sell |
|
|||||
|
2025
Q2 | $7.17M | Sell |
|
|||||
|
2025
Q1 | $6.6M | Sell |
|
|||||
|
2024
Q4 | $8.39M | Buy |
|
|||||
|
2024
Q3 | $6.53M | Sell |
|
|||||
|
2024
Q2 | $7.93M | Sell |
|
|||||
|
2024
Q1 | $8.08M | Sell |
|
|||||
|
2023
Q4 | $7.82M | Sell |
|
|||||
|
2023
Q3 | $6.75M | Sell |
|
|||||
|
2023
Q2 | $5.89M | Sell |
|
|||||
|
2023
Q1 | $6.38M | Sell |
|
|||||
|
2022
Q4 | $7.68M | Sell |
|
|||||
|
2022
Q3 | $6.94M | Sell |
|
|||||
|
2022
Q2 | $6.44M | Buy |
|
|||||
|
2022
Q1 | $6.14M | Buy |
|
|||||
|
2021
Q4 | $3.92M | Buy |
|
|||||
|
2021
Q3 | $4.36M | Sell |
|
|||||
|
2021
Q2 | $4.6M | Sell |
|
|||||
|
2021
Q1 | $4.72M | Buy |
|
|||||
|
2019
Q2 | – | Sell |
|
|||||
|
2019
Q1 | $10.8K | Buy |
|
|||||
|
2018
Q4 | $8.71K | Sell |
|
|||||
|
2018
Q3 | $15.1K | Buy |
|